Navigation Links
Uroplasty To Participate In Two Upcoming Conferences
Date:8/8/2012

MINNEAPOLIS, Aug. 8, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced its participation in two upcoming conferences.

Wedbush Securities PacGrow Life Sciences Conference
Date:  Tuesday, August 14, 2012
Time:  3:40 pm ET
Location:  New York, NY
David Kaysen, President and CEO, will present the Company's strategy and recent corporate developments.

Attendance at the conference is by invitation only.  A live audio webcast of the presentation will be broadcast via the Internet. Those interested in listening to the webcast may access it at  http://wsw.com/webcast/wedbush21/upi/, or through Uroplasty's website at www.uroplasty.com. An archived replay of the presentation will be available for 90 days.

32nd Annual Canaccord Growth Conference
Date:  Wednesday, August 15, 2012
Location:  Boston, MA
David Kaysen will meet with interested investors in a series of one-on-one meetings.

These meetings will not be webcast.

About Uroplasty, Inc.Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians.  Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

 For Further Information:Uroplasty, Inc.

EVC Group  David Kaysen, President and CEO, or

Doug Sherk/Jenifer Kirtland (Investors), 415.568.9349 Medi Jiwani, Vice President, CFO, Treasurer

Chris Gale (Media), 646.201.5431952.426.6140  


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty Reports Fiscal First Quarter 2013 Financial Results
2. Uroplasty to Issue First Quarter of Fiscal 2013 Financial Results on July 26, 2012
3. Uroplasty To Present At The JMP Securities Healthcare Conference
4. Uroplasty Reports Fiscal Fourth Quarter And Full Year 2012 Financial Results
5. Uroplasty Announces Product Development and New Clinical Trial Initiatives
6. Uroplasty to Present at the 11th Annual JMP Securities Research Conference
7. PRA Participates in Landmark Alzheimers Prevention Clinical Trial
8. Misonix Participates In Cleveland Spine Review
9. NIPTE Will Participate in NIHs Therapeutics for Rare and Neglected Diseases (TRND) Program
10. ApolloMed ACO Selected To Participate In A Transformative New Initiative Sponsored by the Centers for Medicare and Medicaid Services
11. ViroPharma To Participate In The JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... March 28, 2017  Orexigen Therapeutics, Inc. (Nasdaq: ... for the fourth quarter and year ended December 31, ... of transformational progress for Orexigen, beginning with the re-acquisition ... Commencing early March, the team at Orexigen demonstrated remarkable ... which reshaped and strengthened our Company while rewarding us ...
(Date:3/28/2017)... BOSTON , March 28, 2017  Market ... today announced a partnership with premium news content ... pharmaceutical companies to extract key insights from Dow ... mining technology. The Linguamatics I2E platform ... 20 global pharmaceutical companies. The Linguamatics-Dow Jones partnership ...
(Date:3/28/2017)... 28, 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ... and commercialization of innovative therapies for the treatment ... Medicines Agency (EMA) has notified the company that ... Authorisation Application (MAA) has passed validation, and that ... The MAA for ARX-04 (known as DSUVIA™ in ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 28, 2017 , ... Resoundant, Inc., the developer of ... Healthineers annual customer education symposium, a world-class learning conference that offers educational content ... - 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , Innovations ...
(Date:3/28/2017)... ... March 29, 2017 , ... The Thyroid ... Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March 1, and ... regarding thyroid function. , Dr. Izabella Wentz is a licensed pharmacist and ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... share of all holidays (IBT World Travel Trends Report). As travelers visit both ... a range in temperatures, and prolonged sun exposure. In response, the outdoor industry ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... the science and clinical practice of radiosurgery, announced today the publication of ... observational registry established to standardize data collection from patients treated with stereotactic ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Alert Sentry ... of MPERS (Mobile Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These ... market. The first of their kind, the iSAFE and iSAFE Plus offer direct GPS ...
Breaking Medicine News(10 mins):